PCT: an aid for risk assessment in COVID-19 secondary bacterial infections
B·R·A·H·M·S PCT (Procalcitonin) is widely used to assess the risk of bacterial infection and progression to severe bacterial sepsis and septic shock in conjunction with other laboratory findings and clinical assessment. Further, the change of PCT over time is used to determine the mortality risk in patients with bacterial sepsis.
In patients with suspected or confirmed lower respiratory tract infections (LRTI), including community acquired pneumonia (CAP), acute bronchitis and acute exacerbations of COPD (AECOPD), PCT is an aid in decision making on antibiotic therapy for inpatients or patients presenting in the emergency department (ED).
Procalcitonin has now been shown, in evolving descriptive studies, to be an additional valuable tool in the current COVID-19 pandemic to early identify patients at low risk for bacterial coinfection and adverse outcome.[1-6,17] Learn more: thermofisher.com/pct-covid-19.